BRIGHT MINDS BIOSCIENCES INC.(DRUG)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
DRUG Stock Analysis & AI Quality Score
AI stock analysis and institutional research for BRIGHT MINDS BIOSCIENCES INC. (DRUG), a Healthcare sector company. DRUG is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Top institutional holders of DRUG by reported 13-F value include JANUS HENDERSON GROUP PLC, Cormorant Asset Management,, BlackRock,, based on the most recent SEC filings. DRUG trades on the Nasdaq exchange and files with the SEC under CIK 1827401. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DRUG daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BRIGHT MINDS BIOSCIENCES INC. directly from SEC EDGAR.
Get alerted when DRUG's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for BRIGHT MINDS BIOSCIENCES INC. including:
Top Institutional Holders of DRUG
JANUS HENDERSON GROUP PLC
$93.5M1,284,324 shCormorant Asset Management, LP
$77.3M1,059,331 shBlackRock, Inc.
$45.4M621,933 shVivo Capital, LLC
$40.7M557,172 shBRAIDWELL LP
$39.4M539,708 shADAGE CAPITAL PARTNERS GP, L.L.C.
$36.2M495,743 shVestal Point Capital, LP
$35.9M492,319 shDRIEHAUS CAPITAL MANAGEMENT LLC
$31.6M432,515 shPERCEPTIVE ADVISORS LLC
$27.5M377,544 shBALYASNY ASSET MANAGEMENT L.P.
$21.7M297,158 sh
| Fund | Value | Shares |
|---|---|---|
| JANUS HENDERSON GROUP PLC | $93.5M | 1,284,324 |
| Cormorant Asset Management, LP | $77.3M | 1,059,331 |
| BlackRock, Inc. | $45.4M | 621,933 |
| Vivo Capital, LLC | $40.7M | 557,172 |
| BRAIDWELL LP | $39.4M | 539,708 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $36.2M | 495,743 |
| Vestal Point Capital, LP | $35.9M | 492,319 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | $31.6M | 432,515 |
| PERCEPTIVE ADVISORS LLC | $27.5M | 377,544 |
| BALYASNY ASSET MANAGEMENT L.P. | $21.7M | 297,158 |
More Healthcare Companies
View all Healthcare →Put DRUG on your watchlist
Track score changes the day BRIGHT MINDS BIOSCIENCES INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is DRUG a good stock to buy?
13F Pro's AI-powered analysis of BRIGHT MINDS BIOSCIENCES INC. (DRUG) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DRUG are available on the DRUG stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own DRUG?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DRUG. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BRIGHT MINDS BIOSCIENCES INC.'s investment landscape.